Kronos Bio, Inc. (NASDAQ:KRON - Get Free Report) CEO Deborah Knobelman sold 24,838 shares of the firm's stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $0.87, for a total value of $21,609.06. Following the completion of the sale, the chief executive officer now directly owns 139,422 shares in the company, valued at approximately $121,297.14. The trade was a 15.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Kronos Bio Stock Up 0.2%
Shares of KRON stock traded up $0.00 on Friday, reaching $0.87. 1,784,799 shares of the stock were exchanged, compared to its average volume of 370,010. The firm has a 50 day moving average of $0.77 and a two-hundred day moving average of $0.89. Kronos Bio, Inc. has a 1-year low of $0.65 and a 1-year high of $1.60. The stock has a market cap of $53.16 million, a P/E ratio of -0.61 and a beta of 1.63.
Kronos Bio (NASDAQ:KRON - Get Free Report) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.13). Kronos Bio had a negative net margin of 867.66% and a negative return on equity of 64.55%. The business had revenue of $2.27 million for the quarter, compared to analyst estimates of $1.00 million. On average, equities research analysts predict that Kronos Bio, Inc. will post -1.36 EPS for the current fiscal year.
Institutional Investors Weigh In On Kronos Bio
Hedge funds have recently bought and sold shares of the business. Kennedy Capital Management LLC grew its stake in Kronos Bio by 8.7% in the fourth quarter. Kennedy Capital Management LLC now owns 149,251 shares of the company's stock worth $142,000 after purchasing an additional 12,007 shares in the last quarter. Velan Capital Investment Management LP acquired a new stake in Kronos Bio in the fourth quarter worth $33,000. GTS Securities LLC bought a new stake in Kronos Bio in the fourth quarter valued at $48,000. Squarepoint Ops LLC bought a new stake in Kronos Bio in the fourth quarter valued at $93,000. Finally, Deuterium Capital Management LLC acquired a new position in shares of Kronos Bio during the first quarter valued at $121,000. Institutional investors and hedge funds own 64.09% of the company's stock.
About Kronos Bio
(
Get Free Report)
Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kronos Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kronos Bio wasn't on the list.
While Kronos Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
